Comparison · NCT03187769-sae
ALKS 3831 vs Olanzapine: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ALKS 3831 vs Olanzapine: serious adverse events. Trial comparisons, record NCT03187769-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03187769-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0379 | 0.0193 | 0.073 | wilson | |
| Risk in group 2 | 0.0372 | 0.019 | 0.0717 | wilson | |
| Risk difference, group 1 minus group 2 | 0.000705 | -0.0385 | 0.0403 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.02 | 0.39 | 2.66 | log | |
| Odds ratio, group 1 over group 2 | 1.02 | 0.376 | 2.77 | log | |
| Number needed to harm, for one more participant with a serious adverse event on ALKS 3831 than on Olanzapine | 1,420 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ALKS 3831 | Coated bilayer tablet~ALKS 3831: Olanzapine + samidorphan, daily oral dosing | 8 | 211 | EG000 |
| Group 2 | Olanzapine | Coated bilayer tablet~Olanzapine: Daily oral dosing | 8 | 215 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 16 Weeks
Source ClinicalTrials.gov
Trial
- Title
- Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
- NCT number
- NCT03187769
- Phases
- PHASE3
- Conditions
- Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder
- Interventions
- ALKS 3831, Olanzapine
- Lead sponsor
- Alkermes, Inc.
- Results first posted
- 2023-01-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03187769?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03187769-sae